Concepedia

Arndt Vogel

AV

1

Publications

31

Citations

1

H-Index

2024

Active since

Affiliations

Union Hospital(Current)

Arndt Vogel is an author at Union Hospital specializing in tumor immunity, oncology, and health sciences.

Top concepts

Publications per year

2024–2024

1

Publications

1

Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.

Arndt Vogel, Stephen L. Chan, Zhenggang Ren et al. · Journal of Clinical Oncology · 2024 · 31 citations

, , +24

Rows per page

1–1 of 1